Quantitative characterisation of extracellular vesicles designed to decoy or compete with SARS-CoV-2 reveals differential mode of action across variants of concern and highlights the diversity of Omicron

Abstract excerpt

BACKGROUND: The converging biology between enveloped viruses and extracellular vesicles (EVs) has raised interest in the application of engineered EVs as antiviral therapeutics. Following the recent COVID-19 pandemic, EVs engineered with either the ACE2-receptor or Spike-protein have been proposed as strategy to either decoy SARS-CoV-2, or to compete with its cell entry. For generic use as a platform for future...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Extracellular vesicles in disease
• Share to interferon and immune responses
• Share to Respiratory viral infections research